MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn

<p><span style="font-weight: 400;">The FDA authorizes a postexposure prophylaxis for COVID-19; a new treatment is okay’d for lupus; a higher dose naloxone nasal spray became available; the risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn. </span></p>